Your session is about to expire
← Back to Search
Phosphate Binder
Phosphate Level Management for Kidney Failure (PHOSPHATE Trial)
N/A
Recruiting
Led By Suetonia Green
Research Sponsored by The University of Queensland
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Currently prescribed at least one phosphate-lowering medication at any dose
Age ≥45 years, or Age ≥18 years with diabetes
Must not have
Elective kidney transplantation scheduled
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 5 years
Awards & highlights
No Placebo-Only Group
Summary
This trial will test whether reducing blood phosphate levels for people with end-stage kidney disease will improve health outcomes and be cost-effective.
Who is the study for?
This trial is for adults with end-stage kidney disease (ESKD) who have been on dialysis for at least 3 months and are taking medication to lower phosphate levels. It's open to those over 45, or over 18 with diabetes, who can consent. People expecting a kidney transplant soon, in other trials affecting phosphate levels, or with illnesses likely causing death within six months cannot join.
What is being tested?
The PHOSPHATE trial is testing whether it's better for patients' health and more cost-effective to aim for high or intensive targets in lowering blood phosphate levels among those with chronic kidney failure. The impact on survival rates, heart events, and physical well-being will be compared.
What are the potential side effects?
While the trial itself may not directly cause side effects, managing phosphate levels could lead to imbalances that affect bone health and muscle function. Phosphate-lowering medications might also cause digestive issues like nausea or diarrhea.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowSelect...
I am currently taking medication to lower my phosphate levels.
Select...
I am 45 or older, or I am 18 or older with diabetes.
Exclusion Criteria
You may be eligible for the trial if you check “No” for criteria below:Select...
I am scheduled for a kidney transplant.
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ 5 years
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~5 years
Treatment Details
Study Objectives
Study objectives can provide a clearer picture of what you can expect from a treatment.Primary study objectives
Time to a composite endpoint of cardiovascular death or non-fatal major cardiovascular event
Secondary study objectives
Utility-based quality of life EQ5D-5L
Other study objectives
Cost-effectiveness analysis
Gastrointestinal Symptom Rating Scale
Itch/pruritus visual analog scale
Awards & Highlights
No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.
Trial Design
2Treatment groups
Experimental Treatment
Active Control
Group I: Intensive phosphate targetExperimental Treatment1 Intervention
Intensive serum phosphate target of ≤1.50 mmol/L.
Group II: Liberal phosphate targetActive Control1 Intervention
Liberal serum phosphate target of 2.0 to 2.5 mmol/L.
Find a Location
Who is running the clinical trial?
The University of QueenslandLead Sponsor
144 Previous Clinical Trials
66,584 Total Patients Enrolled
National Health and Medical Research Council, AustraliaOTHER
166 Previous Clinical Trials
473,277 Total Patients Enrolled
Applied Health Research CentreOTHER
22 Previous Clinical Trials
67,296 Total Patients Enrolled
Media Library
Eligibility Criteria:
This trial includes the following eligibility criteria:- You have a serious illness that could cause death within the next 6 months, according to your doctor.I have been on dialysis for kidney failure for at least 3 months.You are involved in a study that may change the level of phosphate in your blood.I am scheduled for a kidney transplant.I am currently taking medication to lower my phosphate levels.I am 45 or older, or I am 18 or older with diabetes.
Research Study Groups:
This trial has the following groups:- Group 1: Liberal phosphate target
- Group 2: Intensive phosphate target
Awards:
This trial has 1 awards, including:- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
Timeline:
This trial has the following timeline:- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Share this study with friends
Copy Link
Messenger